Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialRavi A. Madan, James L. Gulley, William L. Dahut et al.|The Lancet Oncology|2012Cited by 327